ClinicalTrials.gg
CompletedNCT07805408Updated Sep 4, 2026

A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients

An observational study in Immune Thrombocytopenia, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,714
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Started
2025
with 1 other
Observational
3 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 17th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

The aim of this study was to describe real-world treatment patterns and standard of care treatment effectiveness and utilization outcomes in adult primary ITP patients indicated for second-line treatment with any prior corticosteroid treatment in real-world treatment settings in the United States (US) identified in an electronic health record (EHR) and claims database.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • Primary Immune Thrombocytopenia
  • Retrospective Cohort
  • Treatment Patterns
  • Effectiveness
  • Healthcare Resource Utilization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with primary ITP from a US medical claim and EHR data source during the study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of a diagnosis of primary ITP during the study identification period.
  2. Evidence of treatment with any allowed treatment during the study identification period after the first primary ITP diagnosis.
  3. Evidence of treatment with any allowed first-line treatment prior to index.
  4. Aged ≥18 years at index.

Exclusion criteria

Exclusion criteria

  1. Fewer than 12 months continuous enrollment or activity prior to index.
  2. Fewer than one inpatient or fewer than two outpatient records during baseline.
  3. Evidence of any allowed therapies or splenectomy prior to index.
  4. Evidence of diagnosis of Evans syndrome, systemic lupus erythematosus, lymphoproliferative syndrome, (HIV), virus (HCV), Helicobacter pylori, Sjogren's antiphospholipid syndrome prior to index, or active b-cell (not in remission) in the baseline period.
  5. Continuous enrollment end date or death date prior to index.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,714 participants (actual)
Patient registry
No

Groups and cohorts

  • ITP Cohort

    Primary ITP patients with prior corticosteroid treatment being treated with second-line treatment.

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Patients With Prescribed Second-line Treatments of Interest

    Second-line treatments of interest, either as monotherapy or in a combination therapy, included: * Thrombopoietin Receptor Agonists (TPO-RAs): romiplostim, eltrombopag, avatrombopag. * Clusters of differentiation 20 (CD20) inhibitors: rituximab * Other therapies: fostamatinib * Immunosuppressants: azathioprine, mycophenolate mofetil * Splenectomy

    Time frame: Up to approximately 8 years

Secondary outcomes

  1. Duration of Patient Follow-up

    Time frame: Up to approximately 8 years

  2. Time to Treatment Discontinuation (TTD)

    Time frame: Up to approximately 8 years

  3. Time to Next Treatment (TTNT)

    Time frame: Up to approximately 8 years

  4. Time to Next Treatment or Initiation of Rescue Treatment

    Time frame: Up to approximately 8 years

  5. Number and Percentage of Patients Who Discontinued Treatment Within 1, 3, and 6 Months of Second-line Treatment Initiation

    Time frame: 1, 3, and 6 months

  6. Number and Percentage of Patients by First Type of Activity Observed Following Treatment Discontinuation

    Activities included: * Switch to new treatment * Restart the same second-line treatment * Have rescue treatment without second-line treatment * First-line treatment without second-line treatment * Enter a treatment-free interval * End of EHR/claims disenrollment * Death

    Time frame: 1, 3, and 6 months

  7. Number of Patients Who Entered a Treatment-free Interval

    Treatment free interval was defined as at least 6 months with no second-line treatment or rescue treatment.

    Time frame: Up to approximately 8 years

  8. Duration of Treatment-free Interval

    Treatment free interval was defined as at least 6 months with no second-line treatment or rescue treatment.

    Time frame: Up to approximately 8 years

  9. Number and Percentage of Combination Second-line Treatment Treated Patients Who Underwent Reductions

    Reduction was defined as a discontinuation of at least one therapeutic agent with maintenance of at least one therapeutic agent.

    Time frame: Up to approximately 8 years

  10. Number and Percentage of Patients Who Used Add-on, Rescue, or Supportive Treatment During Second-line Treatment

    An add-on was the inclusion of a new, additional second-line treatment ≥28 days after initiation of the initial second-line treatment.

    Time frame: Up to approximately 8 years

  11. Time to Initiation of Add-on or Rescue Treatment During Second-line Treatment

    Time frame: Up to approximately 8 years

  12. Time to Initiation of Supportive Treatment During Second-line Treatment

    Time frame: Up to approximately 8 years

  13. Platelet Counts

    Time frame: 1, 3, and 6 months

  14. Number and Percentage of Patients Who Achieved Pre-defined Platelet Counts Within 3 Months of Treatment Initiation

    Measured among patients with at least one platelet count within 3 months of treatment initiation. Pre-defined platelet counts were categorized as follows: * ≥30 × 10\^9/L, * ≥ 50 × 10\^9/L, and * ≥100 × 10\^9/L

    Time frame: 3 months

  15. Number and Percentage of Patients With no Initial Response to Second-line Treatment

    Measured among patients with at least one platelet count within 3 months of treatment initiation. No initial response was defined as platelet counts \<30 × 10\^9/L within 3 months of treatment initiation.

    Time frame: 3 months

  16. Number and Percentage of Patients Who Achieved Pre-defined Response Levels Within 6 Months of Treatment Initiation

    Measured among patients with at least one platelet count within 6 months of treatment initiation. Response levels were categorized as follows: * response (≥ 50 × 10\^9/L), and * complete response (≥100 × 10\^9/L)

    Time frame: 6 months

  17. Among Patients With At Least Two Platelet Counts From 3 to 6 Months, Number and Percentage of Patients Who Reached Real-world Durable Response

    Real-world durable response was defined as ≥75% of platelet counts ≥50 × 10\^9/L with a minimum of 2 platelet measurements and without other therapies.

    Time frame: From 3 to 6 months

  18. Among Patients With At Least Two Platelet Counts From 6 to 12 months, Number and Percentage of Patients Who Reached Real-world Durable Response

    Real-world durable response was defined as ≥75% of platelet counts ≥50 × 10\^9/L with a minimum of 2 platelet measurements and without other therapies.

    Time frame: From 6 to 12 months

  19. Number and Percentage of Patients With Emergency Department (ED) or Inpatient (IP) Thrombotic Events Within 12 Months After Second-line Treatment Initiation

    Thrombotic events may have included pulmonary embolism, deep vein thrombosis, cerebral venous thrombosis, transient ischemic attack.

    Time frame: 12 months

  20. Number of Thrombotic Events Within 12 Months After Second-line Treatment Initiation, per 1000 Person-years

    Time frame: 12 months

  21. Number and Percentage of Patients With Infection Events Within 12 Months After Second-line Treatment Initiation

    Time frame: 12 months

  22. Number of Infection Events Within 12 Months After Second-line Treatment Initiation, per 1000 Person-years

    Time frame: 12 months

  23. Number and Percentage of Patients With Bleeding Events Within 12 Months After Second-line Treatment Initiation

    Time frame: 12 months

  24. Number of Bleeding Events Within 12 Months After Second-line Treatment Initiation, per 1000 Person-years

    Time frame: 12 months

  25. Overall Survival (OS)

    Time frame: 12 months

  26. Number and Percentage of Patients With At Least One Healthcare Visit After Second-line Treatment Initiation

    Healthcare visits included outpatient visits, IP admissions, intensive care unit (ICU) admissions, and ED visits.

    Time frame: 12 months

  27. Number of Healthcare Visits After Second-line Treatment Initiation, per Patient per Year (PPPY)

    Healthcare visits included outpatient visits, IP admissions, ICU admissions, and ED visits.

    Time frame: 12 months

  28. Number of Oral Corticosteroid Medication Fills Within 12 Months After Second-line Treatment Initiation, PPPY

    Time frame: 12 months

  29. Number of Days With Active Oral Corticosteroid Prescriptions Within 12 Months After Second-line Treatment Initiation, PPPY

    Time frame: 12 months

  30. Duration of IP and ICU Admissions Among Patients Who Were Hospitalized After Second-line Treatment Initiation

    Time frame: 12 months

  31. Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Failed Treatment

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months. Treatment failure was defined as platelet count \<30 × 10\^9/L.

    Time frame: Up to approximately 8 years

  32. Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Received Rescue Treatment

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.

    Time frame: Up to approximately 8 years

  33. Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Initiated a New Second-line Treatment or Added Oral Corticosteroids

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.

    Time frame: Up to approximately 8 years

  34. Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Died

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.

    Time frame: Up to approximately 8 years

  35. Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Reached the End of the Study Period

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.

    Time frame: Up to approximately 8 years

  36. Among Patient Responders, Time From Second-line Treatment Initiation to Response

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.

    Time frame: Up to 6 months

  37. Among Patient Responders, Duration of Platelet Response

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.

    Time frame: Up to approximately 8 years

  38. Number and Percentage of Patient Responders With Treatment-free Response

    Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months. Treatment-free response was defined as platelet count ≥30 × 10\^9/L at 3 months after discontinuing second-line treatment.

    Time frame: Up to 3 months

07

Study locations

1 site
  • Novartis
    East Hanover, New Jersey 07936, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Nov 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartActual
May 16, 2025
Primary completionActual
Nov 11, 2025
CompletionActual
Nov 11, 2025
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07805408
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
May 16, 2025
Primary completion
Nov 11, 2025
Completion
Nov 11, 2025
Last update
Sep 4, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion